

Clinical Care of Two Patients with Ebola Virus Disease in

New England Journal of Medicine

371, 2402-2409

DOI: [10.1056/nejmoa1409838](https://doi.org/10.1056/nejmoa1409838)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Preparing for Renal Replacement Therapy in Patients with the Ebola Virus Disease. <i>Blood Purification</i> , 2014, 38, 276-285. | 0.9 | 9 |
| 2 | Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014. <i>Viruses</i> , 2014, 6, 4760-4799. | 1.5 | 83 |
| 3 | Out of Africa â€” Caring for Patients with Ebola. <i>New England Journal of Medicine</i> , 2014, 371, 2430-2432. | 13.9 | 14 |
| 4 | Provision of care for Ebola. <i>Lancet, The</i> , 2014, 384, 2105-2106. | 6.3 | 12 |
| 5 | Ebola virus disease. <i>BMJ, The</i> , 2014, 349, g7348-g7348. | 3.0 | 139 |
| 6 | Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease - First Experience with Lectin Affinity Plasmapheresis. <i>Blood Purification</i> , 2014, 38, 286-291. | 0.9 | 38 |
| 8 | The Role of Public Knowledge, Resources, and Innovation in Responding to the Ebola Outbreak. <i>Disaster Medicine and Public Health Preparedness</i> , 2015, 9, 595-597. | 0.7 | 4 |
| 9 | Reaching out to Ebola victims: Coercion, persuasion or an appeal for self-sacrifice?. <i>Social Science and Medicine</i> , 2015, 147, 126-133. | 1.8 | 49 |
| 10 | Laboratory testing in management of patients with suspected Ebolavirus disease: infection control and safety. <i>Pathology</i> , 2015, 47, 400-402. | 0.3 | 6 |
| 11 | Plantâ€produced candidate countermeasures against emerging and reemerging infections and bioterror agents. <i>Plant Biotechnology Journal</i> , 2015, 13, 1136-1159. | 4.1 | 37 |
| 12 | Ethical Issues in the Response to Ebola Virus Disease in United States Emergency Departments: A Position Paper of the American College of Emergency Physicians, the Emergency Nurses Association, and the Society for Academic Emergency Medicine. <i>Academic Emergency Medicine</i> , 2015, 22, 605-615. | 0.8 | 20 |
| 13 | Clinical Management of Ebola Virus Disease: Current and Future Approaches. <i>Topics in Medicinal Chemistry</i> , 2015, , 1-36. | 0.4 | 0 |
| 14 | Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States. <i>Annals of Internal Medicine</i> , 2015, 163, 81-90. | 2.0 | 109 |
| 15 | Active Tracing and Monitoring of Contacts Associated With the First Cluster of Ebola in the United States. <i>Annals of Internal Medicine</i> , 2015, 163, 164-173. | 2.0 | 19 |
| 16 | Ebola at the National Institutes of Health. <i>AACN Advanced Critical Care</i> , 2015, 26, 262-267. | 0.6 | 4 |
| 17 | Working on the front line. <i>Clinical Medicine</i> , 2015, 15, 358-361. | 0.8 | 4 |
| 18 | Ebola virus disease complicated with viral interstitial pneumonia: a case report. <i>BMC Infectious Diseases</i> , 2015, 15, 432. | 1.3 | 36 |
| 20 | Ebola Virus Disease and Marburg Disease in Pregnancy. <i>Obstetrics and Gynecology</i> , 2015, 125, 1293-1298. | 1.2 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 21 | The use of convalescent plasma to treat emerging infectious diseases. <i>Current Opinion in Hematology</i> , 2015, 22, 521-526. | 1.2 | 43 |
| 22 | Critical Care for Multiple Organ Failure Secondary to Ebola Virus Disease in the United States*. <i>Critical Care Medicine</i> , 2015, 43, 2066-2075. | 0.4 | 30 |
| 23 | Rapid Malaria Testing During the 2014 Ebola Epidemic. <i>Point of Care</i> , 2015, 14, 99-101. | 0.5 | 0 |
| 24 | Risks to healthcare workers with emerging diseases. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 349-361. | 1.3 | 119 |
| 25 | Thinking about Ebola. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2015, 45, 15-17. | 0.2 | 2 |
| 26 | Review on Ebola Virus Disease: Its Outbreak and Current Status. <i>Epidemiology (Sunnyvale, Calif)</i> , 2015, 05, . | 0.3 | 1 |
| 27 | Filoviruses: One of These Things is (not) Like the Other. <i>Viruses</i> , 2015, 7, 5172-5190. | 1.5 | 27 |
| 28 | Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis. <i>PLoS Pathogens</i> , 2015, 11, e1005088. | 2.1 | 12 |
| 29 | A Place at the Table for Children in the Ebola Virus Disease Discussion*. <i>Pediatric Critical Care Medicine</i> , 2015, 16, 184-185. | 0.2 | 2 |
| 30 | Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2590-2603. | 1.1 | 16 |
| 31 | Animal models for ebolavirus countermeasures discovery: what defines a useful model?. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 685-702. | 2.5 | 30 |
| 32 | Safety, feasibility, and interest of transthoracic echocardiography in a deployed French military Ebola virus disease treatment center in Guinea. <i>Intensive Care Medicine</i> , 2015, 41, 1491-1492. | 3.9 | 4 |
| 33 | Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 738-745. | 4.6 | 42 |
| 34 | Rethinking the Response to Emerging Microbes: Vaccines and Therapeutics in the Ebola Era—a Conference at Harvard Medical School. <i>Journal of Virology</i> , 2015, 89, 7446-7448. | 1.5 | 6 |
| 35 | Fluid resuscitation in Ebola Virus Disease: A comparison of peripheral and central venous accesses. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2015, 34, 317-320. | 0.6 | 13 |
| 36 | Supportive Care of the First 2 Ebola Virus Disease Patients at the Monrovia Medical Unit. <i>Clinical Infectious Diseases</i> , 2015, 61, e47-e51. | 2.9 | 22 |
| 37 | Will We Be Ready for the Next War?. <i>Clinical Infectious Diseases</i> , 2015, 61, 1488.1-1489. | 2.9 | 2 |
| 38 | Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers. <i>MBio</i> , 2015, 6, e00716. | 1.8 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 39 | Post-Ebola Signs and Symptoms in U.S. Survivors. <i>New England Journal of Medicine</i> , 2015, 373, 2484-2486. | 13.9 | 51 |
| 41 | Tackling emerging infections: clinical and public health lessons from the West African Ebola virus disease outbreak, 2014-2015. <i>Clinical Medicine</i> , 2015, 15, 457-460. | 0.8 | 23 |
| 42 | Lessons for pulmonary critical care from treatment of Ebola virus disease in developed countries. <i>Lancet Respiratory Medicine</i> , 2015, 3, 919-921. | 5.2 | 0 |
| 43 | Treating Ebola patients: a "bottom up" approach using generic statins and angiotensin receptor blockers. <i>International Journal of Infectious Diseases</i> , 2015, 36, 80-84. | 1.5 | 46 |
| 44 | Health-care management of an unexpected case of Ebola virus disease at the Alcorc3n Foundation University Teaching Hospital. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2015, 33, 228-232. | 0.3 | 8 |
| 45 | Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. <i>Lancet Infectious Diseases</i> , 2015, 15, 356-359. | 4.6 | 32 |
| 46 | Human Ebola virus infection results in substantial immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4719-4724. | 3.3 | 274 |
| 47 | Use of the FilmArray System for Detection of Zaire ebolavirus in a Small Hospital in Bo, Sierra Leone. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2368-2370. | 1.8 | 23 |
| 48 | Ebola virus disease: What clinicians in the United States need to know. <i>American Journal of Infection Control</i> , 2015, 43, 788-793. | 1.1 | 15 |
| 49 | The challenges of treating Ebola virus disease with experimental therapies. <i>Lancet Respiratory Medicine</i> , 2015, 3, 503-504. | 5.2 | 1 |
| 50 | Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review. <i>Clinical Infectious Diseases</i> , 2015, 61, 1135-1140. | 2.9 | 43 |
| 51 | Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). <i>Emerging Microbes and Infections</i> , 2015, 4, 1-2. | 3.0 | 11 |
| 52 | Development of experimental and early investigational drugs for the treatment of Ebola virus infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 999-1011. | 1.9 | 7 |
| 53 | Towards deep insight into Ebola virus disease. <i>Lancet Infectious Diseases</i> , 2015, 15, 991-992. | 4.6 | 1 |
| 54 | Editorial Commentary: All's (Almost) Quiet on the Western Front: Will We Be Ready for the Next War?. <i>Clinical Infectious Diseases</i> , 2015, 61, 503-505. | 2.9 | 1 |
| 55 | Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. <i>Lancet Respiratory Medicine</i> , 2015, 3, 554-562. | 5.2 | 113 |
| 56 | Loperamide Therapy for Voluminous Diarrhea in Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2015, 211, 1036-1037. | 1.9 | 25 |
| 57 | Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection: Table 1.. <i>Journal of Infectious Diseases</i> , 2015, 212, S91-S97. | 1.9 | 116 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 58 | The Goals of Research During an Epidemic. <i>American Journal of Bioethics</i> , 2015, 15, 47-50. | 0.5 | 3 |
| 59 | Treatment of Ebola. <i>New England Journal of Medicine</i> , 2015, 372, 1673-1674. | 13.9 | 17 |
| 60 | Ethical Issues in the Response to Ebola Virus Disease in US Emergency Departments: A Position Paper of the American College of Emergency Physicians, the Emergency Nurses Association and the Society for Academic Emergency Medicine. <i>Journal of Emergency Nursing</i> , 2015, 41, e5-e16. | 0.5 | 9 |
| 61 | Pre-hospital transportation in Western countries for Ebola patients, comparison of guidelines. <i>Intensive Care Medicine</i> , 2015, 41, 1472-1476. | 3.9 | 5 |
| 63 | The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. <i>Clinical Infectious Diseases</i> , 2015, 61, 496-502. | 2.9 | 182 |
| 64 | Differential Diagnosis of Illness in Travelers Arriving From Sierra Leone, Liberia, or Guinea: A Cross-sectional Study From the GeoSentinel Surveillance Network. <i>Annals of Internal Medicine</i> , 2015, 162, 757-764. | 2.0 | 34 |
| 65 | Backs against the Wall: Novel and Existing Strategies Used during the 2014-2015 Ebola Virus Outbreak. <i>Clinical Microbiology Reviews</i> , 2015, 28, 593-601. | 5.7 | 42 |
| 66 | Relationship Between Ebola Virus Real-Time Quantitative Polymerase Chain Reaction-Based Threshold Cycle Value and Virus Isolation From Human Plasma. <i>Journal of Infectious Diseases</i> , 2015, 212, S346-S349. | 1.9 | 29 |
| 67 | Targeted Electrolyte Replacement in Patients With Ebola Virus Disease: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1030-1031. | 2.9 | 7 |
| 68 | Clinical Management of Ebola Virus Disease Patients. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 248-260. | 0.8 | 1 |
| 69 | Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit. <i>Intensive Care Medicine</i> , 2015, 41, 735-743. | 3.9 | 25 |
| 70 | Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. <i>Journal of Virology</i> , 2015, 89, 10982-10992. | 1.5 | 120 |
| 71 | Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998. | 13.5 | 326 |
| 72 | Raising the standard for clinical care of patients with Ebola virus disease. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1247-1248. | 4.6 | 6 |
| 73 | Era of global Ebola: risk of exposure in health-care workers. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1248-1249. | 4.6 | 5 |
| 74 | Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1034-1040. | 4.6 | 46 |
| 75 | Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease. <i>Clinical Infectious Diseases</i> , 2015, 61, 969-973. | 2.9 | 75 |
| 76 | Immunomodulatory adjunctive treatment options for Ebola virus disease patients: another view. <i>Intensive Care Medicine</i> , 2015, 41, 1383-1383. | 3.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 77 | Comparison of FilmArray and Quantitative Real-Time Reverse Transcriptase PCR for Detection of Zaire Ebola virus from Contrived and Clinical Specimens. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2956-2960. | 1.8 | 35 |
| 78 | Ebola Virus Infection: Overview and Update on Prevention and Treatment. <i>Infectious Diseases and Therapy</i> , 2015, 4, 365-390. | 1.8 | 33 |
| 79 | Field Evaluation of Capillary Blood Samples as a Collection Specimen for the Rapid Diagnosis of Ebola Virus Infection During an Outbreak Emergency. <i>Clinical Infectious Diseases</i> , 2015, 61, 669-675. | 2.9 | 28 |
| 80 | Ebola and Cholera. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 1081-1081. | 0.6 | 3 |
| 81 | When Potentially Lifesaving Drugs are Both Experimental and in Very Short Supply: A Clinician's Story from the Front Lines of the Battle Against Ebola. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 210-211. | 0.6 | 0 |
| 82 | Twenty-one days of isolation: A prospective observational cohort study of an Ebola-exposed hot zone community in Liberia. <i>Journal of Infection</i> , 2015, 71, 150-157. | 1.7 | 8 |
| 83 | Guidelines for treatment of patients with Ebola Virus Diseases are urgently needed. <i>International Journal of Infectious Diseases</i> , 2015, 30, 85-86. | 1.5 | 5 |
| 84 | Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. <i>Microbiology Spectrum</i> , 2016, 4, . | 1.2 | 3 |
| 85 | West Africa 2013: Re-examining Ebola. <i>Microbiology Spectrum</i> , 2016, 4, . | 1.2 | 16 |
| 87 | Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015. <i>Emerging Infectious Diseases</i> , 2016, 22, . | 2.0 | 13 |
| 88 | Hospital Preparations for Viral Hemorrhagic Fever Patients and Experience Gained from Admission of an Ebola Patient. <i>Emerging Infectious Diseases</i> , 2016, 22, 184-191. | 2.0 | 25 |
| 89 | Ebola Virus RNA Stability in Human Blood and Urine in West Africa's Environmental Conditions. <i>Emerging Infectious Diseases</i> , 2016, 22, 292-294. | 2.0 | 14 |
| 90 | Can't Touch This! Contamination of Laboratory Equipment with Bloodborne Pathogens. <i>Clinical Chemistry</i> , 2016, 62, 910-912. | 1.5 | 0 |
| 91 | Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967. | 3.9 | 382 |
| 92 | Ebola Virus Infection among Western Healthcare Workers Unable to Recall the Transmission Route. <i>BioMed Research International</i> , 2016, 2016, 1-5. | 0.9 | 10 |
| 93 | Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles. <i>PLoS ONE</i> , 2016, 11, e0151842. | 1.1 | 20 |
| 94 | Experimental Treatment of Ebola Virus Disease with Brincidofovir. <i>PLoS ONE</i> , 2016, 11, e0162199. | 1.1 | 78 |
| 95 | The potential of plants as a system for the development and production of human biologics. <i>F1000Research</i> , 2016, 5, 912. | 0.8 | 110 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 96 | Ebola Virus Disease Simulation Case Series. <i>Simulation in Healthcare</i> , 2016, 11, 106-116. | 0.7 | 17 |
| 97 | Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies. <i>Vox Sanguinis</i> , 2016, 110, 329-335. | 0.7 | 18 |
| 98 | Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. <i>Transfusion</i> , 2016, 56, S6-15. | 0.8 | 39 |
| 99 | Spatial Care Paths Strengthen Links in the Chain of Global Resilience. <i>Point of Care</i> , 2016, 15, 43-58. | 0.5 | 7 |
| 100 | Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. <i>Epidemiology and Infection</i> , 2016, 144, 1652-1660. | 1.0 | 78 |
| 102 | The healthcare workers' clinical skill set requirements for a uniformed international response to the Ebola virus disease outbreak in West Africa: the Canadian perspective. <i>Journal of the Royal Army Medical Corps</i> , 2016, 162, 207-211. | 0.8 | 6 |
| 103 | Addressing Infection Prevention and Control in the First U.S. Community Hospital to Care for Patients With Ebola Virus Disease: Context for National Recommendations and Future Strategies. <i>Annals of Internal Medicine</i> , 2016, 165, 41. | 2.0 | 19 |
| 104 | Survey of Ebola Preparedness in Washington State Emergency Departments. <i>Disaster Medicine and Public Health Preparedness</i> , 2016, 10, 662-668. | 0.7 | 11 |
| 105 | Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. <i>Science Translational Medicine</i> , 2016, 8, 329ra33. | 5.8 | 78 |
| 106 | DNA immunization as a technology platform for monoclonal antibody induction. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-12. | 3.0 | 45 |
| 107 | Monitoring of Prognostic Laboratory Markers in Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2016, 213, 1049-1049. | 1.9 | 9 |
| 108 | Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. <i>Cell Death and Disease</i> , 2016, 7, e2164-e2164. | 2.7 | 51 |
| 109 | Responding to the Global Threat of High-Consequence Pathogens: Protecting Health Care Workers and Caring for Patients. <i>Annals of the American Thoracic Society</i> , 2016, 13, 584-585. | 1.5 | 1 |
| 110 | Safe treatment of health-care workers with Ebola. <i>British Journal of Anaesthesia</i> , 2016, 116, 577-579. | 1.5 | 2 |
| 111 | Ebola virus disease: the UK critical care perspective – This Article is accompanied by Editorial Aew068. <i>British Journal of Anaesthesia</i> , 2016, 116, 590-596. | 1.5 | 15 |
| 112 | Clinical Manifestations and Laboratory Diagnosis of Ebola Virus Infection. , 2016, , 117-138. | | 3 |
| 113 | U.S. Ebola Treatment Center Clinical Laboratory Support. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1031-1035. | 1.8 | 21 |
| 114 | Clinical profile and containment of the Ebola virus disease outbreak in two large West African cities, Nigeria, July–September 2014. <i>International Journal of Infectious Diseases</i> , 2016, 53, 23-29. | 1.5 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 115 | Maladie À virus Ebola: actualités thérapeutiques. Journal Des Anti-infectieux, 2016, 18, 117-125. | 0.1 | 2 |
| 116 | Ebola virus disease and critical illness. Critical Care, 2016, 20, 217. | 2.5 | 97 |
| 117 | Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opinion on Investigational Drugs, 2016, 25, 1325-1335. | 1.9 | 34 |
| 118 | Strengthening Health Systems While Responding to a Health Crisis: Lessons Learned by a Nongovernmental Organization During the Ebola Virus Disease Epidemic in Sierra Leone. Journal of Infectious Diseases, 2016, 214, S153-S163. | 1.9 | 64 |
| 119 | Chemical Targeting of a G-Quadruplex RNA in the Ebola Virus L Gene. Cell Chemical Biology, 2016, 23, 1113-1122. | 2.5 | 107 |
| 120 | Assessment of Self-Contamination During Removal of Personal Protective Equipment for Ebola Patient Care. Infection Control and Hospital Epidemiology, 2016, 37, 1156-1161. | 1.0 | 46 |
| 121 | Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences. Journal of Infectious Diseases, 2016, 214, S333-S341. | 1.9 | 11 |
| 122 | Neurological Complications of Ebola Virus Infection. Neurotherapeutics, 2016, 13, 461-470. | 2.1 | 44 |
| 123 | Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nature Immunology, 2016, 17, 1226-1234. | 7.0 | 348 |
| 124 | Plant factories for the production of monoclonal antibodies. Biochemistry (Moscow), 2016, 81, 1118-1135. | 0.7 | 19 |
| 125 | Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Scientific Reports, 2016, 6, 24179. | 1.6 | 33 |
| 126 | Virus fitness differences observed between two naturally occurring isolates of Ebola virus Makona variant using a reverse genetics approach. Virology, 2016, 496, 237-243. | 1.1 | 10 |
| 127 | Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Vaccine Journal, 2016, 23, 717-724. | 3.2 | 40 |
| 128 | Intra-host dynamics of Ebola virus during 2014. Nature Microbiology, 2016, 1, 16151. | 5.9 | 70 |
| 129 | Potent neutralizing monoclonal antibodies against Ebola virus infection. Scientific Reports, 2016, 6, 25856. | 1.6 | 46 |
| 130 | Discovery of an antibody for pan-ebolavirus therapy. Scientific Reports, 2016, 6, 20514. | 1.6 | 83 |
| 131 | Modelling Ebola virus dynamics: Implications for therapy. Antiviral Research, 2016, 135, 62-73. | 1.9 | 26 |
| 132 | Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. Microbiology Spectrum, 2016, 4, . | 1.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 133 | Persistence of Ebola Virus in Convalescence. <i>Current Treatment Options in Infectious Diseases</i> , 2016, 8, 228-236. | 0.8 | 0 |
| 134 | Lassa fever: another threat from West Africa. <i>Disaster and Military Medicine</i> , 2016, 2, 8. | 1.0 | 23 |
| 135 | Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease. <i>Clinical Infectious Diseases</i> , 2016, 63, 460-467. | 2.9 | 50 |
| 136 | Viral haemorrhagic fever in children. <i>Archives of Disease in Childhood</i> , 2016, 101, 461-468. | 1.0 | 7 |
| 138 | Progression of Ebola Therapeutics During the 2014–2015 Outbreak. <i>Trends in Molecular Medicine</i> , 2016, 22, 164-173. | 3.5 | 67 |
| 139 | Sequelae of Ebola virus disease: the emergency within the emergency. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e82-e91. | 4.6 | 127 |
| 140 | The use of GRADE approach in systematic reviews of animal studies. <i>Journal of Evidence-Based Medicine</i> , 2016, 9, 98-104. | 2.4 | 40 |
| 141 | Clinical Management of Ebola Virus Disease in the United States and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 636-646. | 13.9 | 316 |
| 142 | Ebola virus disease diagnosis by real-time RT-PCR: A comparative study of 11 different procedures. <i>Journal of Clinical Virology</i> , 2016, 77, 9-14. | 1.6 | 64 |
| 143 | An Ebola virus-encoded microRNA-like fragment serves as a biomarker for early diagnosis of Ebola virus disease. <i>Cell Research</i> , 2016, 26, 380-383. | 5.7 | 46 |
| 144 | Ebola virus disease: emergence, outbreak and future directions. <i>British Medical Bulletin</i> , 2016, 117, 95-106. | 2.7 | 21 |
| 145 | Implications of plant glycans in the development of innovative vaccines. <i>Expert Review of Vaccines</i> , 2016, 15, 915-925. | 2.0 | 26 |
| 146 | A Health Care Worker with Ebola Virus Disease and Adverse Prognostic Factors Treated in Sierra Leone. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 829-832. | 0.6 | 9 |
| 147 | Antibody Production in Plants and Green Algae. <i>Annual Review of Plant Biology</i> , 2016, 67, 669-701. | 8.6 | 52 |
| 148 | Ebola or Not? Evaluating the Ill Traveler From Ebola-Affected Countries in West Africa. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw005. | 0.4 | 11 |
| 149 | Laboratory diagnosis of Ebola virus disease and corresponding biosafety considerations in the China Ebola Treatment Center. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 326-340. | 2.7 | 6 |
| 150 | Moving Towards a More Aggressive and Comprehensive Model of Care for Children with Ebola. <i>Journal of Pediatrics</i> , 2016, 170, 28-33.e7. | 0.9 | 17 |
| 151 | The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. <i>Clinical Infectious Diseases</i> , 2016, 62, 69-74. | 2.9 | 84 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 152 | Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease. <i>Journal of Infectious Diseases</i> , 2016, 213, 703-711. | 1.9 | 65 |
| 153 | Towards detection and diagnosis of Ebola virus disease at point-of-care. <i>Biosensors and Bioelectronics</i> , 2016, 75, 254-272. | 5.3 | 127 |
| 154 | Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. <i>Critical Reviews in Biotechnology</i> , 2017, 37, 53-68. | 5.1 | 21 |
| 156 | Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. <i>Genome Biology</i> , 2017, 18, 4. | 3.8 | 115 |
| 157 | Immunobiology of Ebola and Lassa virus infections. <i>Nature Reviews Immunology</i> , 2017, 17, 195-207. | 10.6 | 95 |
| 158 | Will There Be a Cure for Ebola?. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 329-348. | 4.2 | 40 |
| 159 | Ebola and Marburg: Out of Africa. , 2017, , 131-154. | | 0 |
| 160 | Candidate medical countermeasures targeting Ebola virus cell entry. <i>Future Virology</i> , 2017, 12, 119-140. | 0.9 | 1 |
| 161 | A systematic review of early modelling studies of Ebola virus disease in West Africa. <i>Epidemiology and Infection</i> , 2017, 145, 1069-1094. | 1.0 | 29 |
| 162 | Neurological Complications and Sequelae of Ebola Virus Disease. <i>Current Infectious Disease Reports</i> , 2017, 19, 19. | 1.3 | 20 |
| 163 | Ebola virus disease and pregnancy: A review of the current knowledge of Ebola virus pathogenesis, maternal, and neonatal outcomes. <i>Birth Defects Research</i> , 2017, 109, 353-362. | 0.8 | 61 |
| 164 | Epidemiology of ebolavirus disease (EVD) and occupational EVD in health care workers in Sub-Saharan Africa: Need for strengthened public health preparedness. <i>Journal of Epidemiology</i> , 2017, 27, 455-461. | 1.1 | 26 |
| 165 | Insights from clinical research completed during the west Africa Ebola virus disease epidemic. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e280-e292. | 4.6 | 69 |
| 166 | The Role of the Laboratory and Transfusion Service in the Management of Ebola Virus Disease. <i>Transfusion Medicine Reviews</i> , 2017, 31, 149-153. | 0.9 | 6 |
| 167 | Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 115-137. | 0.7 | 3 |
| 168 | Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. <i>Scientific Reports</i> , 2017, 7, 45552. | 1.6 | 80 |
| 169 | The ongoing evolution of antibody-based treatments for Ebola virus infection. <i>Immunotherapy</i> , 2017, 9, 435-450. | 1.0 | 20 |
| 170 | Biochemical testing in a laboratory tent and semi-intensive care of Ebola patients on-site in a remote part of Guinea: a paradigm shift based on a bleach-sensitive point-of-care device. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1881-1890. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 171 | The Pathogenesis of Ebola Virus Disease. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 387-418. | 9.6 | 266 |
| 172 | The development of a massive open online course during the 2014-15 Ebola virus disease epidemic. Annals of Epidemiology, 2017, 27, 611-615. | 0.9 | 13 |
| 173 | A gap analysis of the United States death care sector to determine training and education needs pertaining to highly infectious disease mitigation and management. Journal of Occupational and Environmental Hygiene, 2017, 14, 674-680. | 0.4 | 11 |
| 174 | Human monoclonal antibodies as candidate therapeutics against emerging viruses. Frontiers of Medicine, 2017, 11, 462-470. | 1.5 | 38 |
| 176 | Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. Annual Review of Pharmacology and Toxicology, 2017, 57, 155-169. | 4.2 | 23 |
| 177 | Ebola virus disease: An update on current prevention and management strategies. Journal of Clinical Virology, 2017, 86, 5-13. | 1.6 | 25 |
| 179 | Ebola Virus Disease and Hemorrhagic Fevers. , 2017, , 391-400. | | 1 |
| 180 | Risks from <i>Ebolavirus</i> Discharge from Hospitals to Sewer Workers. Water Environment Research, 2017, 89, 357-368. | 1.3 | 25 |
| 181 | Clinical Presentation and Care of Patients with Ebola Virus Disease in the China Ebola Treatment Unit, Liberia. Japanese Journal of Infectious Diseases, 2017, 70, 32-37. | 0.5 | 5 |
| 182 | Assessing Viral Transfer During Doffing of Ebola-Level Personal Protective Equipment in a Biocontainment Unit. Clinical Infectious Diseases, 2018, 66, 945-949. | 2.9 | 33 |
| 183 | Determining training and education needs pertaining to highly infectious disease preparedness and response: A gap analysis survey of US emergency medical services practitioners. American Journal of Infection Control, 2018, 46, 246-252. | 1.1 | 20 |
| 184 | Xylosylation of proteins by expression of human xylosyltransferase 2 in plants. Journal of Bioscience and Bioengineering, 2018, 126, 371-378. | 1.1 | 2 |
| 185 | Public Health Resilience Checklist for High-Consequence Infectious Diseases—Informed by the Domestic Ebola Response in the United States. Journal of Public Health Management and Practice, 2018, 24, 510-518. | 0.7 | 13 |
| 186 | U.S. High-Level Isolation Unit Clinical Laboratory Capabilities Update. Journal of Clinical Microbiology, 2018, 56, . | 1.8 | 5 |
| 187 | Chimeric 3' flanking regions strongly enhance gene expression in plants. Plant Biotechnology Journal, 2018, 16, 1971-1982. | 4.1 | 66 |
| 189 | Filoviruses and Arenaviruses. , 2018, , 1190-1195.e2. | | 0 |
| 190 | Post-exposure treatments for Ebola and Marburg virus infections. Nature Reviews Drug Discovery, 2018, 17, 413-434. | 21.5 | 104 |
| 191 | Management of Ebola Virus Disease in Children. Infectious Disease Clinics of North America, 2018, 32, 201-214. | 1.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 192 | Lessons from the domestic Ebola response: Improving health care system resilience to high consequence infectious diseases. American Journal of Infection Control, 2018, 46, 533-537. | 1.1 | 26 |
| 193 | Hepatitis Caused by Other Viruses. , 2018, , 78-83. | | 3 |
| 194 | Ebolavirus diagnosis made simple, comparable and faster than molecular detection methods: preparing for the future. Virology Journal, 2018, 15, 75. | 1.4 | 25 |
| 195 | Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing. MBio, 2018, 9, . | 1.8 | 58 |
| 197 | The Potential Impact of Border Security Upon Prevalence of Infectious Disease. Disaster Medicine and Public Health Preparedness, 2018, 12, 554-562. | 0.7 | 2 |
| 198 | A Bayesian Belief Network Model Assessing the Risk to Wastewater Workers of Contracting Ebola Virus Disease During an Outbreak. Risk Analysis, 2018, 38, 376-391. | 1.5 | 19 |
| 199 | Beyond binding: antibody effector functions in infectious diseases. Nature Reviews Immunology, 2018, 18, 46-61. | 10.6 | 516 |
| 200 | Testing Experimental Therapies in a Guinea Pig Model for Hemorrhagic Fever. Methods in Molecular Biology, 2018, 1604, 269-278. | 0.4 | 1 |
| 201 | Plant-expressed Fc-fusion protein tetraivalent dengue vaccine with inherent adjuvant properties. Plant Biotechnology Journal, 2018, 16, 1283-1294. | 4.1 | 27 |
| 202 | Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection. Antiviral Research, 2018, 149, 154-163. | 1.9 | 31 |
| 203 | Treatment-focused Ebola trials, supportive care and future of filovirus care. Expert Review of Anti-Infective Therapy, 2018, 16, 67-76. | 2.0 | 9 |
| 204 | Ebola virus disease: an update on post-exposure prophylaxis. Lancet Infectious Diseases, The, 2018, 18, e183-e192. | 4.6 | 112 |
| 205 | Ebola Virus Disease: A Lesson in Science and Ethics. Advances in Research Ethics and Integrity, 2018, , 33-44. | 0.2 | 0 |
| 206 | Ãbola, abordaje clÃnico integral. Revista Facultad De Medicina, 2018, 66, 293-299. | 0.0 | 0 |
| 207 | Life-Threatening Rashes. , 2018, , . | | 3 |
| 208 | Ebola Virus. , 2018, , 291-300. | | 0 |
| 209 | Enhanced expression of dengue virus EDIII-based tetraivalent antigen protein using transgenic rice callus. Plant Biotechnology Reports, 2018, 12, 207-215. | 0.9 | 7 |
| 210 | Enacting high reliability principles while caring for people with Ebola Virus Disease. American Journal of Infection Control, 2018, 46, 1167-1173. | 1.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 211 | Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs. <i>Journal of Infectious Diseases</i> , 2018, 218, S603-S611. | 1.9 | 6 |
| 212 | Vaccines Against West Nile Virus. , 2018, , 121-146. | | 1 |
| 213 | Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2â€™MPER region. <i>Nature Microbiology</i> , 2018, 3, 670-677. | 5.9 | 68 |
| 214 | Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2018, 218, S496-S503. | 1.9 | 25 |
| 215 | The Rise and Rise of <i>Nicotiana benthamiana</i> : A Plant for All Reasons. <i>Annual Review of Phytopathology</i> , 2018, 56, 405-426. | 3.5 | 201 |
| 216 | Ebola Virus Disease. , 0, , 521-525. | | 0 |
| 218 | A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay. <i>Journal of Immunological Methods</i> , 2018, 460, 10-16. | 0.6 | 8 |
| 219 | Recombinant Therapeutic Molecules Produced in Plants. <i>Advances in Botanical Research</i> , 2018, 86, 207-244. | 0.5 | 3 |
| 220 | Ebola Vaccines. , 2018, , 276-287.e5. | | 0 |
| 221 | Vitamin A Supplementation Was Associated with Reduced Mortality in Patients with Ebola Virus Disease during the West African Outbreak. <i>Journal of Nutrition</i> , 2019, 149, 1757-1765. | 1.3 | 21 |
| 222 | Plant-Made Antibodies: Properties and Therapeutic Applications. <i>Current Medicinal Chemistry</i> , 2019, 26, 381-395. | 1.2 | 12 |
| 223 | Comprehensive Clinical Care for Infants and Children with Ebola Virus Disease. <i>Global Maternal and Child Health</i> , 2019, , 67-85. | 0.1 | 0 |
| 224 | Posttranslational Modification of Heterologous Human Therapeutics in Plant Host Expression Systems. , 2019, , 145-169. | | 0 |
| 225 | CRISPR/Cas9-mediated knockout of the RDR6 gene in <i>Nicotiana benthamiana</i> for efficient transient expression of recombinant proteins. <i>Planta</i> , 2019, 250, 463-473. | 1.6 | 25 |
| 226 | Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. <i>BMC Infectious Diseases</i> , 2019, 19, 376. | 1.3 | 30 |
| 227 | Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. <i>Cell</i> , 2019, 177, 1566-1582.e17. | 13.5 | 153 |
| 228 | Marburg virus disease outbreak in Kween District Uganda, 2017: Epidemiological and laboratory findings. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007257. | 1.3 | 42 |
| 229 | Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. <i>Journal of Virology</i> , 2019, 93, . | 1.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 230 | U.S. Medical Examiner/Coroner capability to handle highly infectious decedents. <i>Forensic Science, Medicine, and Pathology</i> , 2019, 15, 31-40. | 0.6 | 13 |
| 231 | Perspectives towards antiviral drug discovery against Ebola virus. <i>Journal of Medical Virology</i> , 2019, 91, 2029-2048. | 2.5 | 35 |
| 232 | Monoclonal antibodies as anti-infective products: a promising future?. <i>Clinical Microbiology and Infection</i> , 2019, 25, 60-64. | 2.8 | 55 |
| 233 | Impact of Intravenous Fluid Therapy on Survival Among Patients With Ebola Virus Disease: An International Multisite Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 1038-1047. | 2.9 | 6 |
| 234 | High Level Production of Monoclonal Antibodies Using an Optimized Plant Expression System. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 472. | 2.0 | 72 |
| 236 | Hemorrhagic Fevers. , 2020, , 119-138. | | 0 |
| 237 | Association between multivitamin supplementation and mortality among patients with Ebola virus disease: An international multisite cohort study. <i>African Journal of Emergency Medicine</i> , 2020, 10, 23-29. | 0.4 | 4 |
| 238 | Ebola Hemorrhagic Shock Syndrome-on-a-Chip. <i>IScience</i> , 2020, 23, 100765. | 1.9 | 35 |
| 239 | Nutritional Care for Patients with Ebola Virus Disease. <i>Emerging Infectious Diseases</i> , 2020, 26, 20-25. | 2.0 | 5 |
| 240 | Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. <i>Pathogens</i> , 2020, 9, 850. | 1.2 | 16 |
| 241 | A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant. <i>Frontiers in Immunology</i> , 2020, 11, 576012. | 2.2 | 9 |
| 242 | Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. <i>Virus Research</i> , 2020, 287, 198108. | 1.1 | 85 |
| 243 | A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , 2020, 584, 120-124. | 18.7 | 1,237 |
| 244 | Production of a structurally validated cyclotide in rice suspension cells is enabled by a supporting biosynthetic enzyme. <i>Planta</i> , 2020, 252, 97. | 1.6 | 6 |
| 245 | Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 385-390. | 1.0 | 4 |
| 247 | Prospects for the Production of Recombinant Therapeutic Proteins and Peptides in Plants: Special Focus on Angiotensin I-Converting Enzyme Inhibitory (ACEI) Peptides. , 0, , . | | 2 |
| 248 | Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13. | 18.1 | 340 |
| 249 | Development of an antibody cocktail for treatment of Sudan virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3768-3778. | 3.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 250 | Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recommendations and Reports, 2021, 70, 1-12. | 26.7 | 37 |
| 251 | Targeting Ebola virus replication through pharmaceutical intervention. Expert Opinion on Investigational Drugs, 2021, 30, 201-226. | 1.9 | 11 |
| 252 | Remote-Controlled and Pulse Pressure-Guided Fluid Treatment for Adult Patients with Viral Hemorrhagic Fevers. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1172-1175. | 0.6 | 4 |
| 253 | Systemic and Oral Immunogenicity of Porcine Epidemic Diarrhea Virus Antigen Fused to Poly-Fc of Immunoglobulin G and Expressed in <i>Nicotiana benthamiana</i> Plants. Frontiers in Pharmacology, 2021, 12, 653064. | 1.6 | 6 |
| 254 | SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. Frontiers in Cellular and Infection Microbiology, 2021, 11, 676451. | 1.8 | 21 |
| 255 | Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?. Vaccines, 2021, 9, 761. | 2.1 | 17 |
| 256 | The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections. Life, 2021, 11, 734. | 1.1 | 34 |
| 258 | Ebolavirus: An Overview of Molecular and Clinical Pathogenesis. Methods in Molecular Biology, 2017, 1628, 39-50. | 0.4 | 6 |
| 259 | The Emerging Threat of Ebola. Advanced Sciences and Technologies for Security Applications, 2020, , 103-139. | 0.4 | 6 |
| 260 | Rights-Based Approaches to Preventing, Detecting, and Responding to Infectious Disease. International Library of Ethics, Law, and the New Medicine, 2020, , 217-253. | 0.5 | 9 |
| 261 | Ebola Virus Disease and Pregnancy: Perinatal Transmission and Epidemiology. Global Maternal and Child Health, 2019, , 53-65. | 0.1 | 5 |
| 262 | West Africa 2013: Re-examining Ebola. , 0, , 1-37. | | 1 |
| 263 | Immunologic timeline of Ebola virus disease and recovery in humans. JCI Insight, 2020, 5, . | 2.3 | 25 |
| 264 | Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight, 2017, 2, e88864. | 2.3 | 60 |
| 265 | Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa. PLoS Medicine, 2015, 12, e1001857. | 3.9 | 20 |
| 266 | Presence and Persistence of Ebola or Marburg Virus in Patients and Survivors: A Rapid Systematic Review. PLoS Neglected Tropical Diseases, 2016, 10, e0004475. | 1.3 | 39 |
| 267 | Enterovirus D-68 Infection, Prophylaxis, and Vaccination in a Novel Permissive Animal Model, the Cotton Rat (<i>Sigmodon hispidus</i>). PLoS ONE, 2016, 11, e0166336. | 1.1 | 28 |
| 268 | Early Identification and Prevention of the Spread of Ebola in the United States. MMWR Supplements, 2016, 65, 75-84. | 15.3 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 269 | BioÉtica e investigaci3n: análisis de caso de la epidemia por el virus del Ébola en 2014. Revista Latinoamericana De BioÉtica, 2016, 17, 124-149. | 0.3 | 1 |
| 270 | Rights-Based Approaches to Preventing, Detecting, and Responding to Infectious Disease Outbreaks. SSRN Electronic Journal, 0, , . | 0.4 | 4 |
| 271 | Preparing for imported Ebola cases in Israel, 2014 to 2015. Eurosurveillance, 2015, 20, . | 3.9 | 10 |
| 272 | Ebola outbreak preparedness and preventive measures among healthcare providers in Saudi Arabia. Journal of Infection in Developing Countries, 2016, 10, 829-836. | 0.5 | 12 |
| 273 | Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari, Sardinia, Italy. Journal of Infection in Developing Countries, 2016, 10, 537-543. | 0.5 | 5 |
| 274 | Ebola at the National Institutes of Health. AACN Advanced Critical Care, 2015, 26, 262-267. | 0.6 | 1 |
| 275 | Ebola virus disease: Essential clinical knowledge. Avicenna Journal of Medicine, 2017, 07, 96-102. | 0.3 | 12 |
| 276 | Filoviruses. , 0, , 981-1007. | | 1 |
| 277 | Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. , 0, , 39-52. | | 0 |
| 278 | Animal-Borne Viruses. , 0, , 515-526. | | 0 |
| 279 | Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. , 0, , 53-71. | | 1 |
| 280 | Characterization of Viral Exposures in United States Occupational Environments. , 2017, , 57-82. | | 0 |
| 281 | Treatment of Viral Hemorrhagic Fever in a Well-Resourced Environment. , 2017, , 485-494. | | 0 |
| 282 | Ebola in West Africa: Biosocial and Biomedical Reflections. Boston Studies in the Philosophy and History of Science, 2017, , 143-164. | 0.4 | 0 |
| 283 | Viral Hemorrhagic Fever Preparedness. , 2018, , 197-211. | | 0 |
| 284 | Escalation (May 23, 2014â€“August 31, 2014). , 2018, , 23-79. | | 0 |
| 286 | Ebola Virus Disease - clinical manifestations, management and future therapies. Journal of the Royal Naval Medical Service, 2019, 105, 113-120. | 0.0 | 0 |
| 287 | Emerging infections and future threats. Erciyes Medical Journal, 0, , . | 0.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 288 | Plant Platform for Therapeutic Monoclonal Antibody Production. , 2019, , 543-581. | | 0 |
| 290 | Treatment of Viral Hemorrhagic Fever in a Well-Resourced Environment. , 2020, , 473-479. | | 0 |
| 291 | Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recommendations and Reports, 2021, 70, 1-12. | 26.7 | 0 |
| 292 | Ebola: Implications and Perspectives. Transactions of the American Clinical and Climatological Association, 2015, 126, 93-112. | 0.9 | 4 |
| 294 | Anemia during Hospitalization in the Patients with Ebola Virus Disease. Iranian Journal of Pathology, 2016, 11, 189-90. | 0.2 | 0 |
| 295 | CRISPR/Cas9-mediated knockout of the DCL2 and DCL4 genes in Nicotiana benthamiana and its productivity of recombinant proteins. Plant Cell Reports, 2022, 41, 307-317. | 2.8 | 7 |
| 296 | Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks. International Journal of Surgery, 2022, 97, 106204. | 1.1 | 17 |
| 297 | Construction of SARS-CoV-2 virus-like particles in plant. Scientific Reports, 2022, 12, 1005. | 1.6 | 26 |
| 298 | Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study. BMC Infectious Diseases, 2022, 22, 71. | 1.3 | 0 |
| 299 | Therapeutic Strategies against Ebola Virus Infection. Viruses, 2022, 14, 579. | 1.5 | 16 |
| 300 | Development and Structural Analysis of Antibody Therapeutics for Filoviruses. Pathogens, 2022, 11, 374. | 1.2 | 7 |
| 302 | Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly. Journal of Biological Chemistry, 2022, 298, 102025. | 1.6 | 4 |
| 304 | Showcasing Environmental Health and Safety Activities During the Coronavirus Disease 2019 Pandemic. Applied Biosafety, 0, , . | 0.2 | 0 |
| 305 | Filoviruses and Arenaviruses. , 2023, , 1213-1219.e2. | | 0 |
| 306 | Sudan virus disease outbreak in Uganda in 2022: the case of patient zero. International Journal of Infectious Diseases, 2023, 128, 318-320. | 1.5 | 7 |
| 307 | A treatise on Ebola virus. , 2023, , 117-124. | | 0 |
| 308 | Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |